Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

Talazoparib For Neoadjuvant Treatment Of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer. A Phase 2, Non-Randomized, Open-Label, Single-Arm, Multi-Center Study of Talazoparib for
Neoadjuvant Treatment of Germline BRCA1/2 Mutation Patients With Early Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer.

Category & Conditions:
Cancer
Medicine:
TALZENNA™(TALAZOPARIB) CAPSULES
ClinicalTrials.gov Identifier (NCT):
Protocol ID:
C3441020
Open Plain Language Summary Result:Click here